Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:probiotic_formulation
|
| gptkbp:administeredBy |
oral formulation
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:contains |
gptkb:Limosilactobacillus_reuteri
glycerol dextran microparticles |
| gptkbp:developedBy |
Scioto Biosciences
|
| gptkbp:effect |
potential improvement in social functioning
|
| gptkbp:intendedUse |
gptkb:autism_spectrum_disorder
|
| gptkbp:mechanismOfAction |
modulation of gut microbiome
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:studiedIn |
clinical trials
|
| gptkbp:targetAudience |
children and adolescents with autism
|
| gptkbp:bfsParent |
gptkb:Antimony
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sb-121
|